Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/28/2007DE102005061756A1 Verbessertes Verfahren zur Herstellung von Ramipril An improved process for the preparation of Ramipril
06/28/2007DE102005061655A1 Diazepinone Diazepinones
06/28/2007DE102005061624A1 Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen An improved process for the preparation of salts of 4- (Benzimidazolylmethylamino) -Benzamidinen
06/28/2007DE102005061623A1 Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen An improved process for preparing 4- (Benzimidazolylmethylamino) -Benzamidinen and salts thereof
06/28/2007DE102005061575A1 Verfahren zur Herstellung optisch aktiver 3-Azido-Carbonsäurederivate und 3-Amino-Carbonsäurederivate A process for preparing optically active 3-azido-carboxylic acid derivatives and 3-amino-carboxylic acid derivatives
06/28/2007DE102005061429A1 Substituierte Oxazol-Derivate Substituted oxazole derivatives
06/28/2007DE102005061427A1 Substituierte Oxadiazol-Derivate Substituted oxadiazole derivatives
06/28/2007DE102005061290A1 Verfahren zur Herstellung von Antibiotikum-/Antibiotika-Partikeln und deren Verwendung A process for producing antibiotic / antibiotics particles and their use
06/28/2007DE102005061071A1 Wirkstoffkombination aus Santalbinsäure oder Derivate davon und Traubenkernöl zur topischen oder dermatologischen Verwendung Combination of active substances santalbic or derivatives thereof, and grape seed oil for topical or dermatological use
06/28/2007DE102005059279A1 Fungizid oder antimykotisch wirkende Verbindungen Fungicide or antifungal acting compounds
06/28/2007DE102005053512A1 Verwendung von Clodronsäure zur Behandlung von Podotrochlose Use of clodronate in the treatment of navicular
06/28/2007DE102005052442A1 Strukturierte Lipidgemische Structured lipid mixtures
06/28/2007CA2824075A1 Combination of r, r-glycopyrrolate, formoterol, and a glucocorticoid for the treatment of inflammatory diseases
06/28/2007CA2673010A1 Compositions comprising one or more phytosterols and/or phytostanols, or derivatives thereof, and high hlb emulsifiers
06/28/2007CA2673005A1 Emulsions comprising non-esterified phytosterols in the aqueous phase
06/28/2007CA2669503A1 Compounds and methods for thiol-containing compound efflux and cancer treatment
06/28/2007CA2634804A1 Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
06/28/2007CA2634724A1 Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
06/28/2007CA2634704A1 Tripodal ligands with the coordinating motifs k2-bh2 or k3-bh3 relevant for biomedical applications of organometallic complexes
06/28/2007CA2634701A1 Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
06/28/2007CA2634699A1 N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
06/28/2007CA2634693A1 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
06/28/2007CA2634644A1 8-pyrazinyl-5-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents
06/28/2007CA2634636A1 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
06/28/2007CA2634608A1 Inhibition de la reponse immunitaire anti-fviii
06/28/2007CA2634491A1 Compositions and methods for modulating gated ion channels
06/28/2007CA2634468A1 Spiroketals
06/28/2007CA2634391A1 3- (4-{ ¬4-(4-{ ¬3-(3, 3-dimethyl-1-piperidinyl) propyl| 0xy} phenyl) -1-piperidinyl| carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders
06/28/2007CA2634379A1 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
06/28/2007CA2634362A1 Organophosphoric derivatives useful as anti-parasitic agents
06/28/2007CA2634359A1 Synephrine derivatives useful as anti-inflammatory agents
06/28/2007CA2634355A1 Bis-platinum complexes with antitumor activity
06/28/2007CA2634349A1 Means and methods for the treatment and prevention of allergic diseases
06/28/2007CA2634305A1 Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
06/28/2007CA2634291A1 Transcription factor decoy oligodeoxynucleotides having multiple cis elements
06/28/2007CA2634258A1 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor
06/28/2007CA2634212A1 Mif inhibitors
06/28/2007CA2634172A1 Piperidine derivatives
06/28/2007CA2634165A1 Pyrrolo [1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof
06/28/2007CA2634158A1 Use of 4, 7-dihydrothieno ¬2, 3-b| pyridine compounds in the treatment of cardiovascular diseases
06/28/2007CA2634152A1 Trpa1 inhibitors for treating pain
06/28/2007CA2634147A1 Calcium channel antagonists
06/28/2007CA2634140A1 Method and composition for treating and diagnosing restless legs syndrome
06/28/2007CA2634116A1 Anti-ilt7 antibody
06/28/2007CA2634072A1 Markers for memory t cells and uses thereof
06/28/2007CA2634059A1 Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
06/28/2007CA2634056A1 Amorphous form of 1,2-dihydropyridine compound
06/28/2007CA2634047A1 Pyrimidinyl aryl urea derivatives being fgf inhibitors
06/28/2007CA2634019A1 Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
06/28/2007CA2633793A1 Methods of clustering gene and protein sequences
06/28/2007CA2633769A1 Crystalline form of vinflunine ditartrate
06/28/2007CA2633570A1 Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
06/28/2007CA2633563A1 Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
06/28/2007CA2633484A1 Condensed heterocyclic compounds useful as dpp-iv inhibitors
06/28/2007CA2633470A1 Combination of a 5-ht4 agonist with a cholinesterase inhibitor
06/28/2007CA2633457A1 Heterocyclic amide derivatives as calcium channel blockers
06/28/2007CA2633425A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives
06/28/2007CA2633351A1 Heterocycle substituted ketone derivatives as histone deacetylase (hdac) inhibitors
06/28/2007CA2633181A1 Salt and polymorph of dpp-iv inhibitor
06/28/2007CA2633149A1 Solid preparation containing an insulin sensitizer
06/28/2007CA2633101A1 Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
06/28/2007CA2633099A1 Treatment of respiratory diseases
06/28/2007CA2633040A1 Composition of inverse emulsion type comprising ivermectin, and uses thereof in cosmetics and dermatology
06/28/2007CA2633010A1 Histone deacetylase inhibitors for enhancing activity of antifungal agents
06/28/2007CA2632936A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
06/28/2007CA2632929A1 Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
06/28/2007CA2632924A1 Chemical compounds
06/28/2007CA2632911A1 Compositions including at least one retinoid compound and at least one anti-irritant compound and uses thereof
06/28/2007CA2632908A1 Ginger extract for inhibiting human drug transporters
06/28/2007CA2632902A1 Compositions including at least one retinoid compound and at least one anti-irritant compound and uses thereof
06/28/2007CA2632881A1 Sulfoximine-substituted pyrimidines, their preparation and use as drugs
06/28/2007CA2632842A1 Process for preparation of water-soluble azole prodrugs
06/28/2007CA2632780A1 Combination of r,r-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases
06/28/2007CA2632582A1 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
06/28/2007CA2632561A1 Substituted propofol derivatives as analgesics
06/28/2007CA2632449A1 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
06/28/2007CA2632444A1 Use of aminoalcohol derivatives for the treatment of overactive bladder
06/28/2007CA2632438A1 Inhibitors of ccr9 activity
06/28/2007CA2632039A1 Bursting pellets
06/28/2007CA2632021A1 Gaba-b receptor modulators
06/28/2007CA2632020A1 Imidazoles as gaba-b receptor modulators
06/28/2007CA2632016A1 Imidazole derivatives for the treatment of gastrointestinal disorders
06/28/2007CA2632011A1 Pyrazoles for the treatment of gerd and ibs
06/28/2007CA2631991A1 Heterocyclic gaba-b modulators
06/28/2007CA2631868A1 Treatment of drug-resistant tumors
06/28/2007CA2631823A1 Ginger fraction for inhibiting human cyp enzymes
06/28/2007CA2631816A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor
06/28/2007CA2631764A1 Combination of zd6474 and pemetrexed
06/28/2007CA2631721A1 Sulphonamidoaniline derivatives being janus kinases inhibitors
06/28/2007CA2631676A1 Combination of azd2171 and pemetrexed
06/28/2007CA2631653A1 Compounds having cytokine modulating properties
06/28/2007CA2631436A1 Inhibitors of ccr9 activity
06/28/2007CA2631432A1 Inhibitors of ccr9 activity
06/28/2007CA2631390A1 Phenoxy acetic acids as ppar delta activators
06/28/2007CA2631347A1 Pyrazinoylguanidine compounds useful in the treatment of inflammatory or allergic conditions
06/28/2007CA2631069A1 Inhibitors of ccr9 activity
06/28/2007CA2630896A1 New compounds
06/28/2007CA2630890A1 Thienopyridine derivatives as modulators of metabotropic glutamate receptors
06/28/2007CA2630889A1 Pyrazine derivatives as epithelial sodium channel blocker
06/28/2007CA2630739A1 New compounds
1 ... 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 3712 3713 ... 7860